Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib + BR in Treatment-Naïve Mantle Cell Lymphoma
NCT06363994Phase 3Recruiting
- Sponsor
- InnoCare Pharma
- Start
- May 2024
- Primary completion
- Jun 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in mantle cell lymphoma (MCL) comparing Orelabrutinib + BR with Placebo + BR (2 arms). Primary endpoints: Dose-limiting toxicity at 28 days and Progression-free Survival at 7 years. Started May 2024; status: recruiting.
02
Drugs
orelabrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT06363994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06363994.